A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor

ABSTRACT: The primary objective of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s).

DISEASE(S): Endometrial Cancer,Solid Tumor,Hepatocellular Carcinoma (hcc), Solid Tumor (st), Colorectal Cancer (crc), Endometrial Cancer(ec),Colorectal Cancer,Colorectal Neoplasms,Carcinoma, Hepatocellular,Endometrial Neoplasms,Liver Neoplasms,Neoplasms,Hepatocellular Carcinoma

PROVIDER: 2310071 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR